DK2110126T3 - Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område - Google Patents

Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Info

Publication number
DK2110126T3
DK2110126T3 DK08007640.9T DK08007640T DK2110126T3 DK 2110126 T3 DK2110126 T3 DK 2110126T3 DK 08007640 T DK08007640 T DK 08007640T DK 2110126 T3 DK2110126 T3 DK 2110126T3
Authority
DK
Denmark
Prior art keywords
active ingredient
liquid
intrapulmonary
instillation
inhalation
Prior art date
Application number
DK08007640.9T
Other languages
English (en)
Inventor
Hasso Prof Dr Meinert
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Application granted granted Critical
Publication of DK2110126T3 publication Critical patent/DK2110126T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK08007640.9T 2008-04-18 2008-04-18 Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område DK2110126T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08007640A EP2110126B9 (de) 2008-04-18 2008-04-18 Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Publications (1)

Publication Number Publication Date
DK2110126T3 true DK2110126T3 (da) 2012-02-27

Family

ID=39708796

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08007640.9T DK2110126T3 (da) 2008-04-18 2008-04-18 Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Country Status (14)

Country Link
US (1) US8986738B2 (da)
EP (1) EP2110126B9 (da)
JP (1) JP4990929B2 (da)
CN (1) CN101559229B (da)
AT (1) ATE532505T1 (da)
AU (1) AU2009201137A1 (da)
BR (1) BRPI0900767A2 (da)
CA (1) CA2662943A1 (da)
DK (1) DK2110126T3 (da)
ES (1) ES2377152T3 (da)
MX (1) MX2009003812A (da)
PL (1) PL2110126T3 (da)
PT (1) PT2110126E (da)
TW (1) TWI417108B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EP2661280B1 (en) 2011-01-04 2018-11-21 Novaliq GmbH O/w-emulsions comprising semifluorinated alkanes
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
PT2806886T (pt) 2012-01-23 2017-03-24 Novaliq Gmbh Composições de proteínas estabilizadas baseadas em alcanos semifluorados
KR102051677B1 (ko) * 2012-04-23 2019-12-03 키에시 파르마슈티시 엣스. 피. 에이. 분무화에 의한 폐계면활성제의 투여를 위한 방법 및 시스템
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
PL2708228T3 (pl) 2012-09-12 2018-11-30 Novaliq Gmbh Kompozycje do przemywania oczu
DK3024484T3 (da) 2013-07-23 2018-10-08 Novaliq Gmbh Stabiliserede antistofsammensætninger
US10925889B2 (en) * 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US11648261B2 (en) * 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US12226478B2 (en) 2019-04-28 2025-02-18 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
DE102021005494A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
DE102021005495A1 (de) 2021-11-06 2023-05-11 Kocher-Plastik Maschinenbau Gmbh Trennvorrichtung
WO2024208750A1 (en) 2023-04-03 2024-10-10 Dermaliq Therapeutics Gmbh Tri-azole antifungal compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5869539A (en) 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20080019926A1 (en) * 2004-04-19 2008-01-24 Marie-Pierre Krafft Lung Surfactant Supplements
DE102005055811A1 (de) * 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen

Also Published As

Publication number Publication date
CN101559229B (zh) 2013-07-31
TW200950809A (en) 2009-12-16
EP2110126B1 (de) 2011-11-09
ATE532505T1 (de) 2011-11-15
US8986738B2 (en) 2015-03-24
CN101559229A (zh) 2009-10-21
MX2009003812A (es) 2009-10-19
US20100008996A1 (en) 2010-01-14
EP2110126A1 (de) 2009-10-21
ES2377152T3 (es) 2012-03-22
JP2009256353A (ja) 2009-11-05
PT2110126E (pt) 2012-02-20
AU2009201137A1 (en) 2009-11-05
TWI417108B (zh) 2013-12-01
CA2662943A1 (en) 2009-10-18
PL2110126T3 (pl) 2012-04-30
JP4990929B2 (ja) 2012-08-01
ES2377152T9 (es) 2013-02-18
HK1135043A1 (en) 2010-05-28
EP2110126B9 (de) 2012-09-19
BRPI0900767A2 (pt) 2010-12-28

Similar Documents

Publication Publication Date Title
PL2110126T3 (pl) Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej
Mayr et al. Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcome
ES2547336T3 (es) Composición tópica para su uso para el tratamiento de enrojecimiento inducido por rosácea
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
BR112014014602A2 (pt) dispositivos de fixação de cateter
CL2008001194A1 (es) Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
BR112012025047A2 (pt) formulações líquidas estabilizadas
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR076388A1 (es) Procedimientos para mejorar la farmocinetica
Sonobe et al. Sulfide intoxication-induced circulatory failure is mediated by a depression in cardiac contractility
JP2009256353A5 (da)
AR056465A1 (es) Composiciones que contienen derivados de taxano
BR112017023170B1 (pt) Dispositivo de banho medicinal e seu uso
CY1113999T1 (el) Σταθερο ετοιμο προς χρηση ενεσιμο σκευασμα παρακεταμολης
Fike et al. Cyclooxygenase contracting factors and altered pulmonary vascular responses in chronically hypoxic newborn pigs
BR112013022414A2 (pt) método para melhorar a rejeição de membrana permeável, agente de tratamento para melhorar a rejeição e membrana permeável
ES2542177T3 (es) Uso de osmolitos obtenidos de bacterias extremófilas para la fabricación de medicamentos inhalables para la prevención y el tratamiento de enfermedades pulmonares y cardiovasculares, así como un dispositivo de inhalación que contiene osmolitos como componentes activos
Crawley et al. Acetaminophen prevents hyperalgesia in central pain cascade
AR059225A1 (es) Sal de citrato, proceso de preparacion y su actividad en terapia
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
AR083337A1 (es) Tratamientos de infeccion por el virus de hepatitis c
Matsumoto et al. Tunicamycin-induced alterations in the vasorelaxant response in organ-cultured superior mesenteric arteries of rats
Sarre et al. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats